| LDR | | 00000nam u2200205 4500 |
| 001 | | 000000431652 |
| 005 | | 20200224103658 |
| 008 | | 200131s2019 ||||||||||||||||| ||eng d |
| 020 | |
▼a 9781392328682 |
| 035 | |
▼a (MiAaPQ)AAI13918038 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 247004 |
| 082 | 0 |
▼a 615 |
| 100 | 1 |
▼a Ryan, Molly Rose. |
| 245 | 10 |
▼a Understanding the Consequences of Oncogenic FGFR Mutations on Drug Resistance, Signaling, and Tumorigenic Potential. |
| 260 | |
▼a [S.l.]:
▼b Yale University.,
▼c 2019. |
| 260 | 1 |
▼a Ann Arbor:
▼b ProQuest Dissertations & Theses,
▼c 2019. |
| 300 | |
▼a 163 p. |
| 500 | |
▼a Source: Dissertations Abstracts International, Volume: 81-01, Section: B. |
| 500 | |
▼a Publisher info.: Dissertation/Thesis. |
| 500 | |
▼a Advisor: Anderson, Karen S. |
| 502 | 1 |
▼a Thesis (Ph.D.)--Yale University, 2019. |
| 506 | |
▼a This item must not be added to any third party search indexes. |
| 506 | |
▼a This item must not be sold to any third party vendors. |
| 520 | |
▼a Fibroblast growth factor receptor 1 (FGFR1) has been implicated in numerous cancer types including squamous cell lung cancer, a subset of non-small cell lung cancer (NSCLC) with a dismal 5-year survival rate. Small molecule inhibitors targeting FGFR 1 are currently in clinical trials, with AZD454 7 being one of the furthest advanced |
| 590 | |
▼a School code: 0265. |
| 650 | 4 |
▼a Pharmacology. |
| 690 | |
▼a 0419 |
| 710 | 20 |
▼a Yale University. |
| 773 | 0 |
▼t Dissertations Abstracts International
▼g 81-01B. |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0265 |
| 791 | |
▼a Ph.D. |
| 792 | |
▼a 2019 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T15492661
▼n KERIS
▼z 이 자료의 원문은 한국교육학술정보원에서 제공합니다. |
| 980 | |
▼a 202002
▼f 2020 |
| 990 | |
▼a ***1008102 |
| 991 | |
▼a E-BOOK |